NextCure posts Q1 net loss of $17.1M; cash $96M; NC410 data at ASCO June 1

NextCure, Inc.

2024-Q1 EPS reported -$0.61

Cash $96.0M as of March 31, 2024, down $12.3M from Q4 2023; expected to fund operations into H2 2026.
Net loss of $17.1M for Q1 2024 vs $16.1M in Q1 2023; R&D $11.4M, G&A $4.4M, restructuring costs $2.5M.
Phase 1b NC410 combo with pembrolizumab data at ASCO June 1, including additional 20 CRC patients.
LNCB74 (B7-H4 ADC) advancing; IND submission planned by year-end with GLP tox studies initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NextCure, Inc. reported first quarter 2024 results: net income Net loss was $17.1 million.

Period: first quarter 2024
Net income: Net loss was $17.1 million
Result: reported results

Exact text from the filing

NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

268 earnings releases filed in the last 30 days. Browse all earnings releases →

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-006543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.